Novo Nordisk (NVO) Tops Q4 EPS by 10c; Lowers Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Eli Lilly & Co. (LLY) sees volatility amid Novo's warning
February 3, 2026 11:46 AM ESTEli Lilly & Co. (NYSE: LLY) stock is volatile following weak guidance from rival Novo Nordisk (NYSE: NVO)
Novo Nordisk's fourth-quarter performance showed a 2% decline in sales and 4% decrease in operating profit at constant exchange rates. Sales in US Operations... MoreNovo Nordisk reports 2025 sales growth, cuts 2026 outlook
February 3, 2026 11:38 AM ESTNovo Nordisk reported 2025 sales growth of 10% and operating profit growth of 6% at constant exchange rates, according to a company statement. The results exceeded the Danish pharmaceutical company's previous guidance of 8% to 11% sales growth and 4% to 7% operating profit growth.
The company's fourth-quarter performance showed a 2% decline in sales and 4% decrease in operating profit at constant exchange... More
Novo Nordisk (NVO) Halted, News Pending
February 3, 2026 11:36 AM ESTNovo Nordisk (NYSE: NVO) Halted, News Pending
TD Cowen Reiterates Buy Rating on Novo Nordisk (NVO)
February 3, 2026 9:33 AM ESTTD Cowen analyst Michael Nedelcovych reiterated a Buy rating and $70.00 price target on Novo Nordisk (NYSE: NVO).
The analyst commented: "CagriSema First Phase III T2D Readout: Solid, But Similar To Mounjaro; Novo reported topline results for Phase III REIMAGINE 2, testing CagriSema in T2D with metformin +/- SGLT2i. At... More
